Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: A California Cancer Consortium phase I and molecular correlative study

Clinical Cancer Research

Volumn 9, Issue 12, 2003, Pages 4356-4362

  Lara Jr , Primo N ^a   Frankel, Paul ^b   Mack, Philip C ^a   Gumerlock, Paul H ^a   Galvin, Irina ^a   Martel, Cynthia L ^a   Longmate, Jeff ^b   Doroshow, James H ^b   Lenz, Heinz Josef ^c   Lau, Derick H M ^a   Gandara, David R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; MOLECULAR MARKER; PACLITAXEL; PLASMINOGEN ACTIVATOR INHIBITOR 1; TIRAPAZAMINE; VASCULOTROPIN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD LEVEL; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CORRELATION ANALYSIS; DEHYDRATION; DRUG FATALITY; DRUG POTENTIATION; DRUG TARGETING; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; HYPOXIA; INFECTION; LIVER TOXICITY; LYMPHOCYTOPENIA; MALE; METABOLIC DISORDER; MYALGIA; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SENSORY NEUROPATHY; SKIN TOXICITY; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA; TUMOR RESISTANCE; UNITED STATES; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CELL HYPOXIA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PACLITAXEL; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIAZINES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 10744226598     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Gray, L. H., Conger, A. D., and Ebert, M. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br. J. Radiol., 26: 638-648, 1953.
2. Denekamp, J., Fowler, J., and Dische, S. The proportion of hypoxic cells in a human tumor. Int. J. Radiat. Oncol. Biol. Phys., 2: 1227-1228. 1977.
3. Moulder, J. E., and Rockwell, S. Tumor hypoxia: its impact on cancer therapy. Cancer Metastasis Rev., 5: 313-341, 1987.
4. Vaupel, P. W., and Hockel, M. Oxygenation status of human tumors: a reappraisal using computerized pO2 histography. In: P. W. Vaupel, D. R. Kelleher, and M. Gunderoth (eds.), Tumor Oxygenation, pp. 220-232. New York: Gustav Fischer, 1995.
5. Brown, J. M. The hypoxic cell: a target for selective cancer therapy - eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res., 59: 5863-5870, 1999.
6. Gatenby, R. A., Coia, L. R., Richter, M. P., Katz, H., Moldofsky, P. J., Engstrom, P., Brown, D. O., Brookland, R., and Broder, G. J. Oxygen tension in human tumors: in vivo mapping using CT guided probes. Radiology, 156: 211-214, 1985.
7. Grau, C., and Overgaard, J. Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor using a local tumor control assay. Radiother. Oncol., 13: 301-309, 1988.
8. Kennedy, K. A., Teicher, B. A., Rockwell, S., and Sartorelli, A. C. The hypoxic tumor cell: a target for selective cancer chemotherapy. Biochem. Pharmacol., 29: 1-8, 1980.
9. Vaupel, P., and Kallinowski, F. Tissue oxygenation of primary and xenotransplanted human tumors. Radiat. Res., 2: 707-712, 1987.
10. Semenza, G. L. Hypoxia inducible factor-1: oxygen homeostasis and disease pathophysiology. Trends Mol. Med., 7: 351-435, 2001.
11. Koong, A. C., Denko, N. C., Hudson, K. M., Schindler, C., Swiersz, L., Koch, C., Evans, S., Ibrahim, H., Le, O. T., Terris, D. J., and Giaccia, A. J. Candidate genes for the hypoxic tumor phenotype. Cancer Res., 60: 883-887, 2000.
12. Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., and Giaccia, A. J. Hypoxia mediated selection of cells with diminished apoptotic potential in solid tumors. Nature (Lond), 379: 88-91, 1996.
13. Rofstad, E. K., and Danielsen, T. Hypoxia induced metastasis of human melanoma cells: involvement of vascular endothelial growth factor-mediated angiogenesis. Br. J. Cancer, 80: 1697-1707, 1999.
14. Brizel, D. M., Sibley, G. S., Prosnitz, L. R., Scher, R. L., and Dewhirst, M. W. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys., 38: 285-289, 1997.
15. Brizel, D. M.. Scully, S. P., Harrelson, J. M., Layfield, L. J., Bean, J. M., Prosnitz, L. R., and Dewhirst, M. W. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res., 56: 941-943, 1996.
16. Hockel, S., Schlenger, K., Vaupel, P., and Hockel, M. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res., 56: 4509-4515, 1996.
17. Zeman, E. M., Brown, J. M., Lemmon, M. J., Hirst, V. K., and Lee, W. W. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int. J. Radiat. Oncol. Biol. Phys., 12: 1239-1242, 1986.
18. Weitman, S., Mangold, G., Marty, J., Dexter, D., Hilsenbeck, S., Rake, J., Juniewicz, P., and Von Hoff, D. Evidence of enhanced in vivo activity using tirapazamine with paclitaxel and paraplatin regimens against the MV-522 human lung cancer xenograft. Cancer Chemother. Pharmacol., 43: 402-408, 1999.
19. Kelly, K., Crowley, J., Bunn, P. A. Jr., Presant, C. A., Grevstad, P. K., Moinpour, C. M., Ramsey, S. D., Wozniak, A. J., Weiss, G. R., Moore, D. E., Israel, V. K., Livingston, R. B., and Gandara, D. R. Randomized Phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest oncology group trial. J. Clin. Oncol., 19: 3210-3218, 2001.
20. Von Pawel, J., Von Roemeling, R., Gatzemeier, U., Boyer, M., Elisson, L. O., Clark, P., Talbot, D., Rey, A., Bulter, T. W., Hirsh, V., et al. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the International CATAPULT I Study Group. J. Clin. Oncol., 18: 1351-1359, 2000.
21. Ng, K., Treat, J., O'Dwyer, P., Friedland, D., and Miller, V. A. A phase I trial of the addition of paclitaxel to tirapazamine (tpz) and cisplatin in patients with advanced non small cell lung cancer. Proc. Am. Soc. Clin. Oncol., 17: 496, 1998.
22. Gandara, D. R., Lara, P. N., Lau, D. H. Raschko, J., Lenz, H. J., and Doroshow, J. H. Tirapazamine (TPZ) plus taxol/carboplatin (carbo): a California Cancer Consortium phase I trial and implications for SWOG 0003. Proc. Am. Soc. Clin. Oncol., 20: 334a, 2001.
23. Gandara, D. R., Lara, P. N., Jr., Goldberg, Z., Le, Q. T., Mack, P. C., Lau, D. H., and Gumerlock, P. H. Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxia. Semin. Oncol., 29: 102-109, 2002.
24. Hoff, P. M., Saad, E. D., Ravandi-Kashani, F., Czerny, E., and Pazdur, R. Phase I trial of i. v. administered tirapazamine plus cyclophosphamide. Anti-Cancer Drugs, 12: 499-503, 2001.
25. Johnson, C. A., Kilpatrick, D., von Roemeling, R., Langer, C., Graham, M. A., Greenslade, D., Kennedy, G., Keenan, E., and O'Dwyer, P. J. Phase I trial of tirapazamine in combination with cisplatin in a single dose every 3 weeks in patients with solid tumors. J. Clin. Oncol., 15: 773-780, 1997.
26. Miller, V. A., Ng, K. K., Grant, S. C., Kindler, H., Pizzo, B., Heelan, R. T., von Roemeling, R., and Kris, M. G. Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer. Ann. Oncol., 8: 1269-1271, 1997.
27. Treat, J., Johnson, E., Langer, C., Belani, C., Haynes, B., Greenberg, R., Rodriguez, R., Drobins, P., Miller W Jr., Meehan, L., McKeon, A., Devin, J., von Roemeling, R., and Viallet, J. Tirapazamine with cisplatin in patients with advanced non-small cell lung cancer: a phase II study. J. Clin. Oncol., 16: 3524-3527, 1998.
28. Bedikian, A. Y., Legha, S. S., Eton, O., Buzaid, A. C., Papadopoulos, N., Coates, S., Simmons, T., Neefe, J., and von Roemeling, R. Phase II trial of tirapazamine combined with cisplatin in chemotherapy of advanced malignant melanoma. Ann. Oncol., 8: 363-367, 1997.
29. Bedikian, A. Y., Legha, S. S., Eton, O., Buzaid, A. C., Papadopoulos, N., Plager, C., McIntyre, S., and Viallet, J. Phase II trial of escalated dose of tirapazamine combined with cisplatin in advanced malignant melanoma. Anticancer Drugs, 10: 735-739, 1999.
30. Shulman, L. N., Buswell, L., Riese, N., Doherty, N., Loeffler, J. S., von Roemeling, R. W., and Coleman, C. N. Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors. Int. J. Radiat. Oncol. Biol. Phys., 44: 349-353, 1999.
31. Craighead, P. S., Pearcey, R., and Stuart, G. A phase I/II evaluation of tirapazamine administered intravenously concurrent with cisplatin and radiotherapy in women with locally advanced cervical cancer. Int. J. Radiat. Oncol. Biol. Phys., 48: 791-795, 2000.
32. Bajou, K., Noel, A., Gerard, R. D., Masson, V., Brunner, N., Holst-Hansen, C., Skobe, M., Fusenig, N. E., Carmeliet, P., Collen, D., and Foidart, J. M. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat. Med., 4: 923-928, 1998.
33. Pluda, J. M. Tumor associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies. Semin. Oncol., 24: 203-218, 1997.
34. Berger, D. P., Herbstrit, L., Dengler, W. A., Marme, D., Mertelsmann, R., and Fiebig, H. H. Vascular endothelial growth factor (VEGF) mRNA expression in human tumor models of different histologies. Ann. Oncol., 6: 817-825, 1995.
35. Nicol, D., Hi, S. I., Walsh, M., Teh, B., Thompson, L., Kennett, C., and Gotley, D. Vascular endothelial growth factor expression is increased in renal cell carcinoma. J. Urol., 157: 1482-1486, 1997.
36. Dosquet, C., Coudert, M. C., Lepage, E., Cabane, J., and Richard, F. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Clin. Cancer Res., 3: 2451-2458, 1997.
37. Shijubo, N., Uede, T., Kon, S., Maeda, M., Segawa, T., Imada, A., Hirasawa, M., and Abe, S. Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am. J. Respir. Crit. Care Med., 160: 1269-1273, 1999.